News from boehringer ingelheim pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 30, 2020, 08:02 ET Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim recently welcomed Yew Looi Liew (YL) as the newly appointed President of U.S. Human Pharma to its U.S. headquarters. Mr. Liew,...

Oct 15, 2020, 08:00 ET Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Boehringer Ingelheim has entered a collaboration with the Yale Clinical and Translational Research Accelerator to launch a study exploring digital...

Oct 13, 2020, 15:05 ET IASLC NACLC 2020: Boehringer Ingelheim presents new data for Gilotrif® in metastatic, squamous cell carcinoma of the lung, and in EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced new data for Gilotrif® (afatinib) which further affirm its activity in squamous cell carcinoma of the lung and,...

Sep 14, 2020, 07:30 ET Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary...

Sep 02, 2020, 08:00 ET Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

Boehringer Ingelheim today announced the final analysis from GioTag, a real-world retrospective, observational study. The study assessed the impact...

Aug 10, 2020, 08:00 ET Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced a new analysis from the GioTag study, which showed that sequential Gilotrif® (afatinib) and osimertinib...
Tune in to the Breathless® Ballad Challenge: Join Bernie Williams in honoring his dad and other heroes by becoming the lyricist to his instrumental song

Jun 17, 2020, 08:37 ET Tune in to the Breathless® Ballad Challenge: Join Bernie Williams in honoring his dad and other heroes by becoming the lyricist to his instrumental song

New York Yankees all-time great and Latin Grammy-nominee Bernie Williams is raising awareness of the disease that took his dad's life – idiopathic...

Jun 15, 2020, 08:00 ET Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire

Boehringer Ingelheim announced today that Dr. Wolfgang Baiker, U.S. Country Managing Director, President and CEO, will retire after 31 years of...

Feb 03, 2020, 08:00 ET New Study Further Supports the Benefits of SPIRIVA RESPIMAT in the Treatment of Asthma

Boehringer Ingelheim today presented results from a new retrospective analysis of real-world data that showed patients prescribed Spiriva® Respimat®...

Oct 16, 2019, 08:00 ET Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CF™ 1)

Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to evaluate a new treatment for cystic...

Sep 09, 2019, 08:00 ET FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev® (nintedanib) as the first and only medicine to...

Aug 12, 2019, 09:00 ET Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative...

May 21, 2019, 08:03 ET Boehringer Ingelheim and Optimum Patient Care Launch First US Primary Care Patient Registry to Improve COPD Care

Boehringer Ingelheim and Optimum Patient Care today announced the creation of a new patient registry, APEX COPD (Advancing the Patient Experience in...

Sep 12, 2018, 13:27 ET Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

Boehringer Ingelheim today announced results from a phase III study, confirming that Cyltezo® is equivalent to Humira®*, with no clinically...

May 21, 2018, 02:00 ET Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

Boehringer Ingelheim Pharmaceuticals, Inc. today announced new presentations at the American Thoracic Society's 2018 annual conference that reinforce ...

Mar 09, 2018, 08:00 ET Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session

Boehringer Ingelheim today announced that important sub-analyses from three major trials will be presented at the American College of Cardiology...

Feb 16, 2018, 08:00 ET New initiative raises awareness of scleroderma through real-life stories of those living with the rare disease

Boehringer Ingelheim today unveils "More Than Scleroderma™: The Inside Story," a new global initiative that highlights the importance of...

Feb 09, 2018, 06:00 ET Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials

Boehringer Ingelheim today announced that their Phase II Alzheimer's disease trials with investigational compound BI 409306 had not met their...

Dec 20, 2017, 10:00 ET Knowledge Of Biosimilars: Survey Of 100+ U.S. Rheumatologists Shows Familiarity But Need For Further Education

A Boehringer Ingelheim survey of U.S. rheumatologists shows familiarity with biosimilars but a need for education. Contact: Boehringer Ingelheim...

Nov 06, 2017, 07:00 ET Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and...

Oct 30, 2017, 09:00 ET Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy

Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments...
New Documentary Film Shines Light on Physical and Emotional Impact of COPD

Sep 19, 2017, 09:00 ET New Documentary Film Shines Light on Physical and Emotional Impact of COPD

A new documentary film, Clear the Air: Opening Up About COPD, which premiered today online, presents the compelling stories of three people who are...

Aug 29, 2017, 09:26 ET Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo™ (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo™, a biosimilar to...

Jul 27, 2017, 09:56 ET Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira®

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is...

Jun 14, 2017, 10:00 ET Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease - IPF - in Honor of his Dad

New York Yankees all-time great Bernie Williams is teaming up with Boehringer Ingelheim to raise awareness of a lung disease called idiopathic...